$3.19
1.54% day before yesterday
Nasdaq, Jul 25, 10:00 pm CET
ISIN
US0345691036
Symbol
ANEB

Anebulo Pharmaceuticals Inc Stock price

$3.19
+1.72 117.01% 1M
+1.69 112.65% 6M
+1.51 89.88% YTD
+0.99 45.00% 1Y
+0.20 6.69% 3Y
-3.81 54.43% 5Y
-3.81 54.43% 10Y
-3.81 54.43% 20Y
Nasdaq, Closing price Fri, Jul 25 2025
-0.05 1.54%
ISIN
US0345691036
Symbol
ANEB
Industry

Key metrics

Basic
Market capitalization
$131.1m
Enterprise Value
$117.8m
Net debt
positive
Cash
$13.3m
Shares outstanding
41.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
9.7
Financial Health
Equity Ratio
93.6%
Return on Equity
-215.1%
ROCE
-61.2%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
- | -
EBIT
$-8.2m | $-9.6m
Net Income
$-7.7m | $-12.2m
Free Cash Flow
$-6.8m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | -
EBIT
12.9% | -15.2%
Net Income
17.8% | -48.2%
Free Cash Flow
24.1%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-0.2
FCF per Share
$-0.2
Short interest
0.6%
Employees
3
Rev per Employee
$0.0
Show more

Is Anebulo Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Anebulo Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Anebulo Pharmaceuticals Inc forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Anebulo Pharmaceuticals Inc forecast:

Buy
88%
Hold
13%

Financial data from Anebulo Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 4.59 4.59
8% 8%
-
- Research and Development Expense 3.64 3.64
19% 19%
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -8.23 -8.23
13% 13%
-
Net Profit -7.69 -7.69
18% 18%
-

In millions USD.

Don't miss a Thing! We will send you all news about Anebulo Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Anebulo Pharmaceuticals Inc Stock News

Neutral
Business Wire
4 days ago
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company” or “Anebulo”), today announced that a Special Committee of independent directors has recommended, and its Board of Directors (the “Board”) has approved, as part of a going pr...
Neutral
Business Wire
3 months ago
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company” or “Anebulo”), today announced financial results for the three months ended March 31, 2025, and recent updates. Third Quarter Fiscal Year 2025 and Subsequent Highlights: Aneb...
Neutral
Business Wire
5 months ago
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company” or “Anebulo”), today announced financial results for the three months ended December 31, 2024, and recent updates. Second Quarter Fiscal Year 2025 and Subsequent Highlights: ...

Company Profile

Anebulo Pharmaceuticals, Inc. engages in the provision of pharmaceutical services. The firm product candidate is ANEB-001, a potent, small molecule cannabinoid receptor antagonist, designed to address the unmet medical need for a specific antidote for cannabinoid overdose. The company was founded by Lawyer Joseph F on April 23, 2020 and is headquartered in Lakeway, TX.

Head office United States
CEO Richard Cunningham
Employees 3
Founded 2020
Website www.anebulo.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today